Image: Courtesy of Ambion SILENCE! HeLa cells transfected with Cy3-labeled GAPDH or Scrambled siRNAs using Ambion's siPORT Lipid Transfection Agent were harvested 48 hours post-transfection. Red: ...

The newest siRNA and miRNA transfection reagent, INTERFERin ®, is specifically made for high transfection efficiency in many cells, leading to either high gene silencing or increased gene expression.

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license ...

In principle, the technical roadmap for the development of RNAi drugs involves identifying target genes, designing siRNA sequences, obtaining siRNA products, conducting siRNA transfection, and ...

Macromolecular-based gene delivery systems have emerged as viable alternatives to non-viral vectors for gene therapy due to ...

NMR-based analysis of impact of siRNA mixing conditions on internal structure of siRNA-loaded LNP. Journal of Controlled Release, 2024; 373: 738 DOI: 10.1016/j.jconrel.2024.07.055 ...

Gene therapy addresses genetic disorders by correcting defective genes, but delivery remains challenging. Viral vectors, while efficient, pose risks ...

Sirius has also received approvals from the U.S. FDA and the China NMPA and has begun Phase 1 studies with SRSD216, a novel siRNA therapeutic for hyperlipoproteinemia in patients with ...

Transfection facilitates the controlled introduction of DNA or RNA, creating new avenues in the exploration of gene functions and cellular pathways without the need to use viral vectors.

Clinical Trial Growth & Future Outlook: Analysis of the 150+ industry-sponsored siRNA clinical trials conducted between 2020 and 2024, with a 79.5% CAGR reflecting significant industry investment.